Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

304 results about "Myalgia" patented technology

Pain or tenderness in one or more muscles which can involve any area of the body.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula
or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC

Muskiness acesodyne ointment of chasing wind, and preparation method

A Chinese medicine 'Rheumatalgia-relieving and pain-alleviating plaster of musk' for treating arthrodynia, myalgia, and sprain is prepared from 7 raw medicines. Its preparing process is also disclosed.
Owner:重庆希尔安药业有限公司

Medicine for treating rheumatism and rheumatoid disease

The invention provides a pharmaceutical for treating rheumatism and rheumatoid diseases. The pharmaceutical is prepared from glossy ganoderma, Chinese quince, notoginseng, safflower, eucommia bark, staghorn, angelica, cyathula root, licorice, glossy privet fruit, wild aconite root, processed monk shood, scorpion, uncaria stem with hooks, hairy birthwort, smilax, himalayan teasel root, cassia twig, dendrobium stem, Chinese ephedra, solomonseal, scurfy pea, Chinese ampelopsis, hawthorn, East Asian tree fern rhizome, long-noded pit viper, black-tail snake, Chinese polyphaga, Chinese honeylocust spine, muscardine silkworm, silkworm excrement, frankincense, myrrh, nux vomica, ledebouriella root, amomun fruit, Chinaroot Greenbrier Rhizome, weeping forsythia, giant mistletoe and coralbean bark. The pharmaceutical is effective in expelling wind dampness, relieving numbness and pain, nourishing the blood and promoting blood circulation and smoothing collaterals and nourishing yin, and is suitable for treating extremity numbness, arthralgia and myalgia, impotence of waist and knees, swelling, deformation and stiffness of joints, etc. caused by retention of arthralgia due to wind cold-dampness and arthralgia due to wind heat-dampness; and the pharmaceutical has reliable effect, less side effect and wide adaptive diseases.
Owner:李克金

Chinese medicine for treating tractures and preparation for making plaster thereof

The present invention discloses a Chinese medicine with the functions of promoting blood circulation, stopping pain, removing blood stasis, promoting the growth of new tissues and eliminating arthralgia and myalgia and preparation process of its adhesive plaster. It is made up by using 8 Chinese medicinal materials of notoginseng, dahurian angelica root, winglass cockroach, ligusticum root, Chinese angelica root, carthamus flower, borneol and camphor as main raw material and adding methyl salicylate, mentha camphor, belladonna liquid extract, chondroitin sulfate, diphenhydramine hydrochloride and dimethyl sulfoxide as auxiliary material through a certain preparation provess.
Owner:SHENYANG HONGYAO GRP CO LTD

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC

Biomarkers for sensitive detection of statin-induced muscle toxicity

The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of statin-induced muscle toxicity.
Owner:ZORA BIOSCIENCES OY

Medicinal plaster for removing stasis, eliminating stagnation and relieving swelling and preparation method thereof

The invention discloses a medicinal plaster for removing stasis, eliminating stagnation and relieving swelling. The effective component of the medicinal plaster is prepared from the following raw materials in parts by weight: 10 to 40 parts of garden balsam stem, 10 to 40 parts of monkshood, 5 to 30 parts of kusnezoff monkshood root, 5 to 20 parts of Chinese angelica, 2 to 15 parts of camphor, 10 to 30 parts of rhubarb, 30 to 60 parts of elderberry, 10 to 20 parts of asarum, 5 to 25 parts of hemlock parsley, 5 to 30 parts of pawpaw, 10 to 30 parts of sappan wood, 2 to 15 parts of safflower, 5 to 25 parts of slenderstyle acanthopanax bark, 10 to 30 parts of drynaria rhizome, 10 to 30 parts of eupolyphaga, 5 to 20 parts of frankincense, 20 to 40 parts of myrrh, 5 to 20 parts of borneol, and 10 to 40 parts of dragon's blood. The medicinal plaster has excellent functions of activating blood circulation to remove stasis, dispelling wind and eliminating dampness, diminishing inflammation and removing swelling, softening and eliminating stagnation, and clearing and activating the channels and collaterals, helps a patient relieve pains, and can be used for treating lumbar spondylosis, cervical spondylosis, hyperosteogeny, fasciitis, arthralgia and myalgia, osteoarthritis, arthromeningitis, scapulohumeral periarthritis, mastitis, carcinoma part, nodule swelling, trauma and gout. According 1200 cases in nearly 3 years, the cure rate or effective rate of the medicinal plaster is 98 percent.
Owner:徐晓光 +1

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula
or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC

Solid pharmaceutical composition containing atorvastatin calcium

The invention relates to a solid pharmaceutical composition containing atorvastatin calcium as well as a preparation and an application thereof. Specifically, the solid pharmaceutical composition containing atorvastatin calcium can be further prepared into an enteric-coated tablet through a certain preparation process. According to the solid pharmaceutical composition containing atorvastatin calcium, the condition that the atorvastatin calcium in common tablets is degraded into lactone form in gastric acid environment to lose lipid lowering activity; due to the decrease of lactone type impurities, the occurrence rate of the untoward effect myalgia can be reduced. Accelerated stability studies find that the prepared enteric-coated tablet containing atorvastatin calcium is stable in quality and controllable and is capable of providing an effective atorvastatin calcium oral solid preparation for clinic tests.
Owner:SHANGHAI BOCIMED PHARMA CO LTD

Babu far infrared medicinal plaster for treating arthralgia and myalgia, and wind-cold syndrome and numbness

The invention aims to provide a cataplasm far-infrared medical application for treating arthralgia, myalgia, wind cold and numbness, which is elaborately developed by adopting rare pure traditional Chinese medicinal materials, a scientific novel method and a novel process. The application takes a formula in portion by weight: 40 g of borneol, 20 g of frankincense, 20 g of myrrh, 10 g of safflower, 10 g of panax notoginseng, 20 g of pangolin, 60 g of garden balsam stem, 20 g of common clubmoss herb and 400 g of colophony. The main composition of the formula is the pangolin, namely pangolin scales which is salty in taste and slightly cold in property, mainly treats wind cold and limbs numbness, and has the efficacy of dehumidifying, dissolving turbidity, diminishing inflammation and removing pain. The medical application has chlorpheniramine maleate and methyl salicylate which are effective compositions of western medicine added in preparation process, and uses far-infrared powder and biological magnetic powder which are the latest scientific achievements. The application has the advantages of clear effective compositions, obvious efficacy, few side effects, stable preparation and strict quality standard, thereby meeting the requirements of modern Chinese medicine on safety, high efficiency, stability and controllability.
Owner:牛天卓

Making method of Chinese chestnut and mushroom particle drink

The invention discloses a making method of a Chinese chestnut and mushroom particle drink and belongs to the field of drink processing. The making method is characterized by including three processing technological processes of firstly, Chinese chestnut cleaning, baking, soaking and boiling, pulping, filtering and Chinese chestnut pulp forming; secondly, mushroom soak cleaning, pelleting, heat leaching, filtering, leaching liquor forming and mushroom particle forming; thirdly, Chinese chestnut pulp and mushroom particle mixing and blending, homogenizing, bottling, sterilizing, cooling and finished product forming. The making method has the advantages that the drink is fragrant and sweet in juice, mushroom particles are moderate in size, the taste is fine and smooth, the faint scent of mushrooms and the fragrant and sweet flavor of the Chinese chestnuts are achieved, the sweetness is proper, the human immunity can be easily improved, the special curative effect is achieved for preventing osteoporosis and arthralgia and myalgia, the effects of delaying senescence, prolonging life, reducing blood pressure and blood fat and preventing and resisting cancer are achieved, and the drink is a green drink which is delicious, healthy, natural and pure; operation is easy, and implementation is easy.
Owner:朱娜娜

Medicine for treating rheumatism and rheumatoid diseases

The invention provides a medicine for treating rheumatism and rheumatoid diseases. The medicine is prepared from the following Chinese herbal medicines in part by weight: 9 parts of lucid ganoderma, 7 parts of papaya, 7 parts of notoginseng root, 7 parts of safflower, 12 parts of eucommia bark, 18 parts of common clubmoss herb, 8 parts of Chinese angelica, 11 parts of medicinal cyathula root, 6 parts of liquoric root, 3.5 parts of prepared kusnezoff monkshood root, 4.5 parts of prepared common monkshood mother root, 4.2 parts of scorpion, 12.5 parts of gambir plant, 8 parts of himalayan teasel root, 6 parts of cassia twig, 9 parts of dendrobium, 7.5 parts of ephedra herb, 14 parts of siberian solomonseal rhizome, 7 parts of malaytea scurfpea fruit, 7 parts of east asian tree fern rhizome, 4 parts of little multibanded krait, 6 parts of garter snake, 6 parts of Chinese honeylocust spine, 6 parts of stiff silkworm, 5 parts of frankincense, 5 parts of myrrh, 0.5 part of prepared nux vomica, 8 parts of divaricate saposhnikovia root, 8 parts of tuckahoe and 25 parts of medlar. The medicine has the effects of expelling wind-damp, relieving pain or numbness, nourishing blood, promoting blood circulation, dredging collaterals and nourishing yin, and is suitable for treating symptoms of deadlimb, arthralgia and myalgia, waist-leg weakness, arthrocele, dysarthrosis, sluggish flexion and extension of joints and the like which are caused by anemofrigid-damp arthralgia and rheumatic pyretic arthralgia retention.
Owner:李克金
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products